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eTATE-OF-THE-ART PAPER515Herbal Supplements in Cardiac Patientsra Tachjian, Viqar Maria, Arshad Jahangir
ore than 15 million people in the U.S. consume herbal remedies or high-dose vitamins.
he potential risk of adverse herb-drug-disease interactions in cardiac patients who may be
aking multiple prescriptions is reviewed by Tachjian and colleagues. Despite the paucity of
cientific evidence supporting the safety or efficacy of herbal products, they are widely
romoted in the popular media with unsubstantiated health care claims. The possibility of
arm caused either directly or through interactions with prescription medications is reviewed
nd suggestions for improving their safety are proffered.VIEWPOINT IEWPOINT526More Evidence Needed to Guide Treatment of HFNEFalter J. Paulus, Joris J. M. van Ballegoij
aulus and van Ballegoij explore the discrepancies in the literature showing positive effects of
any interventions for patients with heart failure with reduced left ventricular ejection
raction (HFREF) but no significant benefit for those with heart failure and normal left
entricular ejection fraction (HFNEF). The patient recruitment criteria of 21 HFNEF trials
re reviewed in reference to diagnostic guidelines for HFNEF as inclusion/exclusion criteria.
mong these trials, left ventricular ejection fraction (LVEF) cut-off values ranged from 35%
o 50%, with only 8 trials requiring an LVEF 50%. Only 1 trial specified a normal left
entricular (LV) end-diastolic dimension, and only 7 required evidence of diastolic LV
ysfunction. Nonadherence to diagnostic guidelines may have blunted the possible benefit of
ntervention. Future HFNEF trials should adhere to diagnostic guidelines for HFNEF that
equire signs and/or symptoms of heart failure, evidence of normal systolic LV function, and
vidence of diastolic dysfunction.(continued on page A-25)
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cNTERVENTIONAL CARDIOLOGY538Endovascular Stenting for Vertebral Artery Stenosis. Stephen Jenkins, Samir N. Patel, Christopher J. White, Tyrone J. Collins, John P. Reilly,
aul W. McMullan, Mark A. Grise, Arthur G. Grant, Stephen R. Ramee
ymptomatic vertebral artery stenosis (VAS) portends a 30% to 35% 5-year risk of stroke
ith medical therapy, but surgical bypass is rarely performed due to high morbidity and
ortality. Jenkins and colleagues report their results with 105 consecutive symptomatic
atients who underwent stent placement for extracranial (91%) and intracranial (9%) VAS.
rocedural and clinical success was achieved in 100% and 90.5% of patients, respectively. At
-year follow-up, 80% of patients remained symptom-free and only 5% had suffered a
osterior circulation stroke. Stenting for symptomatic VAS can be safely performed and may
ffer a safer approach than either open surgical revascularization or medical therapy.NTERVENTIONAL CARDIOLOGY543ZES Noninferior to PES, But Results Are Mixedartin B. Leon, Laura Mauri, Jeffrey J. Popma, Donald E. Cutlip, Eugenia Nikolsky,
harles O’Shaughnessy, Paul A. Overlie, Brent T. McLaurin, Stuart L. Solomon, John S. Douglas, Jr,
ichael W. Ball, Ronald P. Caputo, Ash Jain, Thaddeus R. Tolleson, Bernard M. Reen III, Ajay J. Kirtane,
eter J. Fitzgerald, Kweli Thompson, David E. Kandzari, for the ENDEAVOR IV Investigators
he ENDEAVOR IV trial is a prospective, randomized trial comparing a zotarolimus-
luting stent (ZES) with a paclitaxel-eluting stent (PES) for single de novo coronary artery
esions. The primary hypothesis was a noninferiority test with regard to 9-month target vessel
ailure (TVF), which was defined as cardiac death, myocardial infarction (MI), or target vessel
evascularization. The ZES was found to be noninferior, with a TVF rate of 6.6% versus
.1% for PES. However, there were differences in the particular end points, with fewer
eriprocedural MIs with ZES (0.5% vs. 2.2%), but a numerically higher rate of in-segment
estenosis (15.3% vs. 10.4%). Based on the TVF end point, ZES is noninferior to PES, but
ore studies are needed to determine if the tradeoff between reduced periprocedural MI and
igher restenosis is real, and ultimately beneficial for patients.ditorial Comment: E. Magnus Ohman, Robert M. Califf, p. 555NTIPLATELET THERAPY558No Evidence of Platelet Hypersensitivity After Abrupt Cessation of Clopidogrelirk Sibbing, Julia Stegherr, Siegmund Braun, Julinda Mehilli, Stefanie Schulz, Melchior Seyfarth,
dnan Kastrati, Nicolas von Beckerath, Albert Schömig
linical studies have reported a clustering of thrombotic events shortly after stopping
lopidogrel treatment, suggesting that there may be a rebound phenomenon. Sibbing
nd colleagues studied this issue and whether tapering of the clopidogrel dose, rather
han abrupt cessation, may be superior. Seventy patients who were finishing their
lopidogrel therapy were randomized to either a tapering regimen for 4 weeks or to abruptly
iscontinue clopidogrel. Platelet aggregation (PA) was assessed with light transmission
ggregometry and multiple electrode aggregometry weekly. PA was found to be similar after
omplete cessation of clopidogrel between both groups. The course of PA values after
lopidogrel cessation provides no evidence for the existence of a rebound phenomenon.
(continued on page A-26)
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rARDIAC RESYNCHRONIZATION THERAPY566Optimal LV Pacing Site Varies Unpredictablyicolas Derval, Paul Steendijk, Lorne J. Gula, Antoine Deplagne, Julien Laborderie, Frederic Sacher,
ebastien Knecht, Matthew Wright, Isabelle Nault, Sylvain Ploux, Philippe Ritter, Pierre Bordachar,
tephane Lafitte, Patricia Réant, George J. Klein, Sanjiv M. Narayan, Stephane Garrigue, Mélèze Hocini,
ichel Haissaguerre, Jacques Clementy, Pierre Jaïs
erval and colleagues used a micromanometer catheter to measure dP/dtmax and other
emodynamic variables while subjects were paced through an endocardial pacing catheter
laced at 11 specific points in the left ventricle (LV) and compared it to a traditional position
n the coronary sinus (CS). Major interindividual and intraindividual variations of
emodynamic response depending on the LV pacing site were observed. Compared with
aseline, LV DDD pacing at the best LV position significantly improved dP/dtmax (31%)
nd was superior to pacing the CS (15%), or the latest activated LV wall as determined by
issue Doppler imaging (11%). The pacing site is a primary determinant of the
emodynamic response to LV pacing, but determining the optimal site appears to require
rial and error.ditorial Comment: Jagmeet P. Singh, William T. Abraham, p. 576EART RHYTHM DISORDERS579Results From a Registry of Laser Lead Extractionsussama Wazni, Laurence M. Epstein, Roger G. Carrillo, Charles Love, Stuart W. Adler,
avid W. Riggio, Shahzad S. Karim, Jamil Bashir, Arnold J. Greenspon, John P. DiMarco,
oshua M. Cooper, John R. Onufer, Kenneth A. Ellenbogen, Stephen P. Kutalek, Sherri Dentry-Mabry,
arolyn M. Ervin, Bruce L. Wilkoff
azni and colleagues examined the safety and efficacy of laser-assisted lead extraction
LALE) in almost 1,500 consecutive patients at 13 centers. Leads were completely removed
n 96%, with a 98% clinical success rate. Failure to achieve clinical success was more common
n patients with a body mass index 25 kg/m2 and in low extraction volume centers. Major
dverse events in 20 patients were directly related to the lead extraction procedure (1.4%),
ncluding 4 deaths (0.28%). LALE is highly successful with a low procedural complication
ate, but mortality from pocket infections or device-related endocarditis remains high.(continued on page A-32)
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vEART RHYTHM DISORDERS587Compound and Digenic Heterozygosity May Be Common in ARVCianhong Xu, Zhao Yang, Matteo Vatta, Alessandra Rampazzo, Giorgia Beffagna, Kalliopi Pillichou,
teven E. Scherer, Jeffrey Saffitz, Joshua Kravitz, Wojciech Zareba, Gian Antonio Danieli,
lessandra Lorenzon, Andrea Nava, Barbara Bauce, Gaetano Thiene, Cristina Basso,
ugh Calkins, Kathy Gear, Frank Marcus, Jeffrey A. Towbin, for the Multidisciplinary Study of
ight Ventricular Dysplasia Investigators
rrhythmogenic right ventricular cardiomyopathy (ARVC) is frequently the result of a
utation in 1 of the 7 genes encoding desmosomal proteins, with autosomal dominant
nheritance, but reduced penetrance. Xu and colleagues sequenced the plakophilin-2 (PKP2)
ene in 198 probands of families with ARVC. Twenty-one variants were found, with 19% of
he probands having at least 1 variant. In 9 of the 38 (24%) probands, PKP2 variants were
dentified that were encoded in trans and, therefore, represent compound heterozygosity, or
he inheritance of 2 distinct mutations. These 38 probands were also screened for other
esmosomal mutations; second variants (digenic heterozygosity) were identified in 42%. These
ata suggest that the genetic basis of ARVC may require a “double-hit” with compound and
igenic heterozygosity.ARDIAC IMAGING
598RI-Based Oximetry May Be Useful for
Measuring Tissue Ischemia in Patients With PADichael C. Langham, Thomas F. Floyd, Emile R. Mohler III, Jeremy F. Magland, Felix W. Wehrli
agnetic resonance imaging (MRI)-based oximetry is a technique that can measure the
ractional volume of deoxyhemoglobin in erythrocytes. Langham and colleagues tested if this
echnique could evaluate vascular function in the lower extremities by making direct time-
ourse measurements of oxygen saturation in the femoral and popliteal arteries and veins
uring cuff-induced reactive hyperemia. Significantly longer washout time of the desaturated
lood and a slower upslope of the return of oxygenated blood were observed in patients with
eripheral arterial disease, compared with healthy subjects. Post-occlusive transient changes in
enous blood oxygenation provide a measure of vascular competence.
